Vaxcyte, Inc. (PCVX)
| Market Cap | 10.38B +83.0% |
| Revenue (ttm) | n/a |
| Net Income | -1.06B |
| EPS | -7.65 |
| Shares Out | 157.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 976,066 |
| Open | 67.72 |
| Previous Close | 67.55 |
| Day's Range | 65.45 - 68.33 |
| 52-Week Range | 39.87 - 90.75 |
| Beta | 1.23 |
| Analysts | Strong Buy |
| Price Target | 117.30 (+77.78%) |
| Est. Earnings | Nov 3, 2026 |
About PCVX
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused b... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for PCVX stock is "Strong Buy." The 12-month stock price target is $117.3, which is an increase of 77.78% from the latest price.
News
Vaxcyte 7.412M share Spot Secondary priced at $64.00
BTIG, Jefferies, Leerink, BofA, Goldman Sachs and Evercore ISI acted as joint book running managers for the offering.
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings...
Vaxcyte price target raised to $146 from $130 at BofA
BofA raised the firm’s price target on Vaxcyte (PCVX) to $146 from $130 and keeps a Buy rating on the shares. Based on Opus-1 results, the firm believes VAX-31 has…
Vaxcyte files to sell $500M of common stock, $500M of convertible senior notes
Vaxcyte (PCVX) announced that it has commenced underwritten public offerings of $500M of its common stock and pre-funded warrants and $500M aggregate principal amount of convertible senior notes due 2...
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of ...
Vaxcyte price target raised to $122 from $110 at Needham
Needham raised the firm’s price target on Vaxcyte (PCVX) to $122 from $110 and keeps a Buy rating on the shares after the company announced topline results from the OPUS-1…
Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.
Vaxcyte data hit ‘blue-sky’ case, says Jefferies
After Vaxcyte (PCVX) announced topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating its VAX-31 31-valent pneumococcal conjugate vaccine candidate, Jefferies analyst Roger Song said t...
Vaxcyte can trade in $90-$100 range on data, says Mizuho
Mizuho says Vaxcyte’s (PCVX) VAX-31 Phase 3 data this morning are “very clean” and “near best-case scenario.” Mizuho believes it will be very difficult to refute that VAX-31 is showing…
Vaxcyte Transcript: Study result
VAX-31 met all 32 pre-specified primary immunogenicity assessments and immunobridged across age groups, with safety similar to licensed comparators. BLA submission is targeted for H1 2028, pending remaining studies and manufacturing work.
Vaxcyte Press release: Study result
Vaxcyte issued a press release on October 5, 2026, disclosing material business information to investors.
Vaxcyte Slides: Study result
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on October 5, 2026.
Vaxcyte price target raised to $125 from $116 at Guggenheim
Guggenheim raised the firm’s price target on Vaxcyte (PCVX) to $125 from $116 and keeps a Buy rating on the shares, which remain a Top Pick. The adult VAX-31 OPUS-1…
Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial
Vaxcyte said on Monday its experimental pneumococcal vaccine generated immune responses comparable to rival vaccines in a late-stage study, sending its shares up 57% in morning trading.
Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31
Vaxcyte (PCVX) announced positive topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the company’s next-generation 31-valent ...
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate
VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate
SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, Oc...
Mizuho biotech analysts hold an analyst/industry conference call
Biotech AnaLyst Syed, along with the Biotech Research Team, discuss Vaxcyte (PCVX), ahead of VAX-31 Ph3 OPUS-1 readout this October, as well as BBIO, RCUS, CYTK, ELVN, IOVA, BIIB on…
Vaxcyte price target lowered to $130 from $133 at BofA
BofA lowered the firm’s price target on Vaxcyte (PCVX) to $130 from $133 and keeps a Buy rating on the shares. Vaxcyte’s upcoming Phase 3 Opus-1 readout is “a major…
Vaxcyte Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
OPUS-1 phase III data for VAX-31, targeting broader pneumococcal coverage and improved immune response, will be released by end of October. Commercial and manufacturing strategies are in place, with a focus on resolving current market trade-offs and scaling post-data.
Vaxcyte Transcript: Wells Fargo 21st Annual Healthcare Conference
The session highlighted advances in vaccine technology enabling broader and more effective pneumococcal vaccines, with pivotal phase III data for VAX-31 expected by October. Regulatory momentum and market dynamics favor broader coverage, and a novel group A strep vaccine is advancing in early trials.
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
Vaxcyte (PCVX) announced the appointments of Luis Jodar as chief medical officer and David McAvoy as chief legal officer. Jodar spent 17 years at Pfizer (PFE), most recently as senior…